PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Antitumor Memory T-Cells Become Functionally Mature from 30 to 100 days in a Mouse Model of Neoplasia.

Abstract Late metastases develop from cancer of the breast, prostate, lung, kidney and malignant melanomas. Memory T-cells have excellent potential to prevent this devastating development in the same way that they routinely prevent emergence of latent viruses.
PMID
Related Publications

The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.

Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.

Memory Antitumor T-Cells Resist Inhibition by Immune Suppressor Cells.

Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer.

Viral infection of implanted meningeal tumors induces antitumor memory T-cells to travel to the brain and eliminate established tumors.

Authors

Mayor MeshTerms

Immunotherapy

Oncolytic Virotherapy

Keywords

Memory T-cells

immunotherapy

oncotherapy

vesicular stomatitis virus

Journal Title anticancer research
Publication Year Start




PMID- 29277767
OWN - NLM
STAT- MEDLINE
DCOM- 20180101
LR  - 20180101
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - Antitumor Memory T-Cells Become Functionally Mature from 30 to 100 days in a
      Mouse Model of Neoplasia.
PG  - 147-157
AB  - BACKGROUND: Late metastases develop from cancer of the breast, prostate, lung,
      kidney and malignant melanomas. Memory T-cells have excellent potential to
      prevent this devastating development in the same way that they routinely prevent 
      emergence of latent viruses. MATERIAL AND METHODS: A peritoneal tumor mouse model
      of viral oncotherapy was used to generate therapeutic antitumor memory T-cells.
      Functional in vivo and in vitro assays were used to study the temporal evolution 
      of their anticancer effects. RESULTS: Highly therapeutic antitumor memory was
      generated by viral oncolytic immunotherapy 30 days after treatment and matured to
      maximal potency at 100 days. Maturation was not uniform across different
      measures. CONCLUSION: The results provide guidelines for developing a viral
      oncolytic vaccine strategy to generate antitumor memory T-cells that can
      eliminate small nests of metastatic cancer cells in sanctuary sites and prevent
      emergence of tumors from dormant cancer cell collections. The results are
      relevant to any immunization strategy designed to generate antitumor memory
      T-cells.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Gao, Yanhua
AU  - Gao Y
AD  - Department of Pediatrics, Children's Hospital of Pittsburgh, University of
      Pittsburgh School of Medicine, Pittsburgh, PA, U.S.A.
FAU - Barmada, Mamdouha A
AU  - Barmada MA
AD  - MMA-NMD Lab, Department of Pathology and Laboratory Medicine, American University
      of Beirut Medical Center, American University Hospital, Beirut, Lebanon.
FAU - Bergman, Ira
AU  - Bergman I
AD  - Department of Pediatrics, Children's Hospital of Pittsburgh, University of
      Pittsburgh School of Medicine, Pittsburgh, PA, U.S.A. [email protected]
AD  - Department of Neurology, Children's Hospital of Pittsburgh, University of
      Pittsburgh School of Medicine, Pittsburgh, PA, U.S.A.
AD  - Department of Immunology, Children's Hospital of Pittsburgh, University of
      Pittsburgh School of Medicine, Pittsburgh, PA, U.S.A.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
SB  - IM
MH  - Animals
MH  - Cell Differentiation
MH  - Disease Models, Animal
MH  - Female
MH  - *Immunotherapy
MH  - Mice, Inbred BALB C
MH  - *Oncolytic Virotherapy
MH  - Peritoneal Neoplasms/immunology/*therapy
MH  - T-Lymphocytes/*cytology/*immunology
MH  - Vesiculovirus
OTO - NOTNLM
OT  - Memory T-cells
OT  - immunotherapy
OT  - oncotherapy
OT  - vesicular stomatitis virus
EDAT- 2017/12/27 06:00
MHDA- 2018/01/02 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/10/18 00:00 [received]
PHST- 2017/11/09 00:00 [revised]
PHST- 2017/11/10 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2018/01/02 06:00 [medline]
AID - 38/1/147 [pii]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):147-157.